Zydus Lifesciences Limited
ZYDUSLIFE
Rang in aandelen
#1755
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aandeelprijs
$12.29
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$12.26B
Verandering (1 dag)
-1.01%
Verandering (1 jaar)
7.78%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Categorie
Healthcare
Operationele marge voor Zydus Lifesciences Limited (ZYDUSLIFE)
Operationele marge op October 2026 TTM: 18.58%
Volgens de meest recente financiële rapporten en aandelenkoers van Zydus Lifesciences Limited is de huidige operationele marge (TTM) 18.58%. Eind 2024 had het bedrijf een operationele marge van 38.86%.
Geschiedenis van de operationele marge van Zydus Lifesciences Limited van 2004 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 18.58% | -55.03% |
| 2025 | 41.32% | 6.33% |
| 2024 | 38.86% | 143.64% |
| 2023 | 15.95% | -2.51% |
| 2022 | 16.36% | -11.09% |
| 2021 | 18.40% | 20.89% |
| 2020 | 15.22% | -18.91% |
| 2019 | 18.77% | -5.35% |
| 2018 | 19.83% | 21.73% |
| 2017 | 16.29% | -23.12% |
| 2016 | 21.19% | 23.13% |
| 2015 | 17.21% | 23.02% |
| 2014 | 13.99% | -6.48% |
| 2013 | 14.96% | 26.35% |
| 2012 | 11.84% | -42.07% |
| 2011 | 20.44% | 9.13% |
| 2010 | 18.73% | 4.23% |
| 2009 | 17.97% | 11.96% |
| 2008 | 16.05% | -3.25% |
| 2007 | 16.59% | -22.59% |
| 2006 | 21.43% | 41.83% |
| 2005 | 15.11% | -2.33% |
| 2004 | 15.47% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.77% |
IN
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.